Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) Receives $73.33 Average Price Target from Brokerages

Shares of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) have earned a consensus rating of “Buy” from the fourteen analysts that are covering the stock, Marketbeat Ratings reports. Four analysts have rated the stock with a hold rating and ten have issued a buy rating on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $73.33.

A number of research firms recently issued reports on RARE. Leerink Swann reaffirmed a “positive” rating and issued a $85.00 target price (up previously from $80.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, September 4th. Piper Jaffray Companies set a $75.00 price target on Ultragenyx Pharmaceutical and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Cowen reissued a “buy” rating and set a $62.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, November 5th. JPMorgan Chase & Co. reissued a “buy” rating and issued a $75.00 price target on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. Finally, BidaskClub upgraded Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Thursday, November 21st.

In other news, CEO Emil D. Kakkis bought 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 11th. The shares were purchased at an average price of $43.63 per share, for a total transaction of $218,150.00. Following the completion of the transaction, the chief executive officer now owns 472,479 shares in the company, valued at $20,614,258.77. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 7.80% of the company’s stock.

Several large investors have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD lifted its position in Ultragenyx Pharmaceutical by 31.7% during the second quarter. Price T Rowe Associates Inc. MD now owns 4,611,939 shares of the biopharmaceutical company’s stock worth $292,858,000 after buying an additional 1,110,316 shares during the period. Orbimed Advisors LLC increased its stake in shares of Ultragenyx Pharmaceutical by 948.0% during the 3rd quarter. Orbimed Advisors LLC now owns 834,313 shares of the biopharmaceutical company’s stock valued at $35,692,000 after acquiring an additional 754,706 shares during the last quarter. Nuveen Asset Management LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 6,239.7% during the 2nd quarter. Nuveen Asset Management LLC now owns 275,081 shares of the biopharmaceutical company’s stock worth $17,467,000 after acquiring an additional 270,742 shares during the period. First Light Asset Management LLC purchased a new position in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth about $11,431,000. Finally, Macquarie Group Ltd. boosted its position in shares of Ultragenyx Pharmaceutical by 19.6% in the second quarter. Macquarie Group Ltd. now owns 797,293 shares of the biopharmaceutical company’s stock worth $50,628,000 after acquiring an additional 130,561 shares during the last quarter.

RARE traded up $0.21 during midday trading on Tuesday, reaching $43.00. 397,900 shares of the company’s stock were exchanged, compared to its average volume of 549,120. Ultragenyx Pharmaceutical has a 1-year low of $35.41 and a 1-year high of $74.50. The stock has a market capitalization of $2.46 billion, a PE ratio of -5.82 and a beta of 2.16. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.79 and a quick ratio of 6.64. The business’s 50-day moving average price is $39.78 and its 200 day moving average price is $51.02.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.96) EPS for the quarter, missing the consensus estimate of ($1.71) by ($0.25). Ultragenyx Pharmaceutical had a negative net margin of 470.18% and a negative return on equity of 52.16%. The business had revenue of $25.80 million during the quarter, compared to analyst estimates of $28.88 million. During the same quarter in the prior year, the company earned ($1.74) earnings per share. The firm’s revenue for the quarter was up 119.4% compared to the same quarter last year. As a group, analysts expect that Ultragenyx Pharmaceutical will post -7.28 EPS for the current fiscal year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.

Further Reading: Moving Average Convergence Divergence (MACD)

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.